Reference number : 236-2017-2018-Q2-00251, amendment number : , agreement type : G, recipient legal name : Dobrin, Anton, recipient country : US, recipient province : nan, recipient city : New York, recipient postal code : nan, program name english : nan, program name french : nan, program purpose english : nan, program purpose french : nan, agreement title english : nan, agreement title french : nan, agreement number : nan, agreement value : 105000.0, agreement start date : 2017-09-01, agreement end date : 2020-08-31, description english : Evaluation of novel cancer immunotherapies that combine the potency of chimeric antigen receptors and the intracellular targeting of T-cell receptors, description french : Evaluation of novel cancer immunotherapies that combine the potency of chimeric antigen receptors and the intracellular targeting of T-cell receptors, expected results english : nan, expected results french : nan, additional information english : Grant or Award spanning more than one fiscal year.
(2017-18 to 2020-21)

Start date may be subject to change.  Funding for awards must commence within 12 months of the date of offer., additional information french : Subvention ou bourse octroyée s'appliquant à plus d'un exercice financier.
(2017-18 à 2020-21)

La date de début peut être sujet au changement.  Le financement des bourses doit commencer dans les 12 mois suivant la date à laquelle elles ont été offertes., owner organization : cihr-irsc, owner organization title : Canadian Institutes of Health Research | Instituts de recherche en santé du Canada